Australia markets closed

SAVA Jan 2024 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.25000.0000 (0.00%)
As of 02:35PM EST. Market open.
Full screen
Previous close2.2500
Open2.5000
Bid0.0000
Ask0.0000
Strike20.00
Expiry date2024-01-19
Day's range2.2500 - 2.5400
Contract rangeN/A
Volume9
Open interestN/A
  • Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

    With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...

  • GlobeNewswire

    Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

    Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.MRI safety data suggests simufilam is not associated with ARIA.$142.4 Million in cash and cash equivalents at September 30, 2023. AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc

  • GlobeNewswire

    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

    1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025. AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate